Journal Article

DZNE-2026-00698

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Assessment of early-phase [18F]florbetaben images as a proxy for brain metabolism in mouse models of Alzheimer's disease.

Gröger, R. ; Englert, A. L. ; Lalia, M. ; de Weerd, L.DZNE* ; Rovere, M.Extern* ; Kunze, L.Extern* ; Palumbo, G. ; Wind, K.Extern* ; Fixemer, S.DZNE* ; Roemer-Cassiano, S. N. ; Franzmeier, N. ; Höglinger, G.DZNE* ; Zwergal, A. ; Tahirovic, S.DZNE* ; Werner, R. A. ; Brendel, M.DZNE* ; Gnörich, J. (Last author)DZNE*

2026
Sage London

This record in other databases:    

Please use a persistent id in citations: doi:10.1177/0271678X261420082

Abstract: [18F]FDG-PET and β-amyloid-PET are established tools for assessing biomarker status in Alzheimer's disease. In this study, we evaluated the potential of early-phase [18F]florbetaben (FBB) PET as a functional proxy for [18F]FDG-PET in preclinical Alzheimer's disease models by examining regional perfusion and glucose metabolism in two transgenic mouse lines. Ninety-two APPPS1 (n = 17), APPSAA (n = 56), and age- and sex-matched wild-type mice (n = 19; 3-12 months, 40% female) underwent static [18F]FDG-PET (30-60 min p.i.) and dynamic [18F]FBB-PET (0-60 min p.i.). Standardized uptake values were derived for both [18F]FDG-PET and [18F]FBB-PET for the whole brain and 14 Ma-Benveniste-Mirrione atlas regions. We identified the 1-3 min p.i. time window as optimal, yielding the highest concordance with [18F]FDG (R = 0.53, p < 0.0001) across all regions. Both APPPS1 and APPSAA mice exhibited significant increases in perfusion (both p < 0.0001) and glucose metabolism (APPPS1: p = 0.0028; APPSAA: p < 0.0001) compared to wild-type controls. These findings demonstrate that early-phase [18F]FBB-PET not only mirrors [18F]FDG-PET-derived metabolic changes but also enables a single-scan assessment of β-amyloid pathology and brain function, thereby reducing the number of required scans and potentially the number of animals per study, and strengthening the translational value of preclinical PET research.

Keyword(s): Animals (MeSH) ; Alzheimer Disease: metabolism (MeSH) ; Alzheimer Disease: diagnostic imaging (MeSH) ; Positron-Emission Tomography: methods (MeSH) ; Stilbenes (MeSH) ; Brain: metabolism (MeSH) ; Brain: diagnostic imaging (MeSH) ; Female (MeSH) ; Mice, Transgenic (MeSH) ; Aniline Compounds (MeSH) ; Mice (MeSH) ; Disease Models, Animal (MeSH) ; Fluorodeoxyglucose F18 (MeSH) ; Male (MeSH) ; Radiopharmaceuticals (MeSH) ; Glucose: metabolism (MeSH) ; Amyloid beta-Protein Precursor: genetics (MeSH) ; Alzheimer’s disease ; FDG PET ; early-phase β-amyloid PET ; mouse ; perfusion ; Stilbenes ; 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene ; Aniline Compounds ; Fluorodeoxyglucose F18 ; Radiopharmaceuticals ; Glucose ; Amyloid beta-Protein Precursor

---

Contributing Institute(s):

1. Molecular Neurodegeneration (AG Haass)
2. Juvenile Neurodegeneration (AG Tahirovic)
3. Clinical Research (Munich) (Clinical Research (Munich))

Research Program(s):

1. 352 - Disease Mechanisms (POF4-352) (POF4-352)
2. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; National-Konsortium ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---